研究者業績

熊野 恵城

クマノ ケイキ  (KUMANO KEIKI)

基本情報

所属
武蔵野大学 薬学部 教授
学位
博士(医学)(1999年3月 東京大学)

J-GLOBAL ID
201801003635316249
researchmap会員ID
B000327851

学歴

 2

論文

 104
  • Kazuhiko Ishigaki, Keiki Kumano, Kyohei Fujita, Hiroo Ueno
    Scientific Reports 11(1) 2021年12月  
    <title>Abstract</title>Although the physiological function of the omentum remains elusive, it has been proposed that it plays an important role in fat storage, immune regulation, and regeneration of injured tissues and organs. Although the omentum undergoes expansion upon activation, reports on the accurate assessment of increased cell types and the origin of the increased cells remain limited. To investigate this aspect, the omenta of parabiotic mice were subjected to activation using distinct fluorescent markers and single-cell RNA sequencing (scRNA-seq) was performed to identify circulation-derived omental cells. We found that a considerable number of circulating cells contributed to the activation of the omentum. The omental cells derived from circulating cells exhibited morphological features similar to those of fibroblasts. scRNA-seq revealed the existence of a novel cell population that co-expressed macrophage and fibroblast markers in the activated omentum, suggesting that it corresponded to circulating macrophage-derived fibroblast-like cells. Lineage tracing experiments revealed that most fibroblasts in the activated omentum were not derived from WT1-positive mesenchymal progenitors. The cell cluster also expressed various chemokine genes, indicating its role in the activation and recruitment of immune cells. These results provide important information regarding the activation of the omentum.
  • Matsukawa, T, Yamamoto, T, Honda, A, Toya, T, Ishiura, H, Mitsui, J, Tanaka, M, Hao, A, Shinohara, A, Ogura, M, Kataoka, K, Seo, S, Kumano, K, Hosoi, M, Narukawa, N, Yasunaga, A, Maki, H, Ichikawa, M, Nannya, Y, Imai, Y, Takahashi, T, Takahashi, Y, Nagasako, Y, Yasaka, K, Koshi Mano K, Kawabe Matsukawa, M, Miyagawa, T, Hamada, M, Sakuishi, K, Hayashi, T, Iwata, A, Terao, Y, Shimizu, J, Goto, J, Mori, M, Kunimatsu, A, Aoki, S, Hayashi, S, Nakamura, F, Arai, S, Monma, K, Ogata, K, Yoshida, T, Abe, O, Inazawa, J, Toda, T, Kurokawa, M, Tsuji, S
    Brain Communications 2(1) fcz048 2020年1月  査読有り
  • Taoka K, Arai S, Kataoka K, Hosoi M, Miyauchi M, Yamazaki S, Honda A, Aixinjueluo W, Kobayashi T, Kumano K, Yoshimi A, Otsu M, Niwa A, Nakahata T, Nakauchi H, Kurokawa M
    Scientific reports 8(1) 15855-15855 2018年10月26日  査読有り
  • Masashi Miyauchi, Junji Koya, Shunya Arai, Sho Yamazaki, Akira Honda, Keisuke Kataoka, Akihide Yoshimi, Kazuki Taoka, Keiki Kumano, Mineo Kurokawa
    Stem cell reports 10(3) 1115-1130 2018年3月13日  査読有り
    Properties of cancer stem cells involved in drug resistance and relapse have significant effects on clinical outcome. Although tyrosine kinase inhibitors (TKIs) have dramatically improved survival of patients with chronic myeloid leukemia (CML), TKIs have not fully cured CML due to TKI-resistant CML stem cells. Moreover, relapse after discontinuation of TKIs has not been predicted in CML patients with the best TKI response. In our study, a model of CML stem cells derived from CML induced pluripotent stem cells identified ADAM8 as an antigen of TKI-resistant CML cells. The inhibition of expression or metalloproteinase activity of ADAM8 restored TKI sensitivity in primary samples. In addition, residual CML cells in patients with optimal TKI response were concentrated in the ADAM8+ population. Our study demonstrates that ADAM8 is a marker of residual CML cells even in patients with optimal TKI response and would be a predictor of relapse and a therapeutic target of TKI-resistant CML cells.
  • Hirotsugu Yanai, Naho Atsumi, Toshihiro Tanaka, Naohiro Nakamura, Yoshihiro Komai, Taichi Omachi, Kiyomichi Tanaka, Kazuhiko Ishigaki, Kazuho Saiga, Haruyuki Ohsugi, Yoko Tokuyama, Yuki Imahashi, Shuichi Ohe, Hiroko Hisha, Naoko Yoshida, Keiki Kumano, Masanori Kon, Hiroo Ueno
    SCIENTIFIC REPORTS 7(1) 9891 2017年8月  査読有り

MISC

 45

書籍等出版物

 2

主要な講演・口頭発表等

 30

担当経験のある科目(授業)

 20

共同研究・競争的資金等の研究課題

 22